Combined Shareholders’ Meeting of 31 May 2023

This article or press release has no online content. Please download the associated documents for more information.

Associated Documents

2023-Convening-Notice.pdf
Voting-form.pdf
Participate-in-the-Shareholders-Meeting.pdf
2022-Universal-registration-document-Ipsen.pdf
Report-of-the-Board-of-Directors-on-the-draft-resolutions.pdf
Preliminary-notice-to-the-Meeting-published-at-the-BALO-on-21-April-2023-French-version.pdf
Preliminary-notice-to-the-Meeting-published-at-the-BALO-on-21-April-2023-Translation-for-information.pdf
Documents-availability-2023-Ipsen-Combined-Shareholders-Meeting.pdf
Statutory-Auditors-Report-–-2022-Financial-Statements.pdf
Statutory-Auditors-Report-–-2022-Consolidated-Financial-Statements.pdf
Statutory-Auditors-special-report-on-regulated-agreements.pdf
Statutory-Audit-Report-resolutions-2023-CSM-in-French.pdf
Total-number-of-voting-rights-and-shares-as-of-21-April-2023.pdf
Convening-Notice-to-the-Meeting-published-at-the-BALO-on-12-May-2023-French-version.pdf
Convening-Notice-to-the-Meeting-published-at-the-BALO-on-12-May-2023-Translation-for-information.pdf

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023